LGM Pharma Invests $6M in U.S. Drug Manufacturing Capabilities

LGM Pharma, announced an investment of over $6 million to expand its Rosenberg, Texas manufacturing facility as part of its Phase I CDMO growth strategy. The expansion will increase capacity for liquid, suspension, semi-solid, and suppository drug products, addressing the rising demand for reliable U.S.-based production.

This investment comes as LGM Pharma experiences sustained growth in prescription drug projects, including 505(b)(2) and Abbreviated New Drug Application (ANDA) programs. The Rosenberg facility enhancements will accommodate increased production volumes while ensuring compliance with FDA regulations and current good manufacturing practices (cGMP). The site will remain fully operational throughout the expansion.

“LGM Pharma is making strategic investments to support the growing need for high-quality domestic drug manufacturing,” said Prasad Raje, Ph.D., CEO of LGM Pharma. “We have several prescription products in development, including both 505(b)(2) and ANDA projects, with one ANDA already submitted to the FDA. This expansion ensures we can continue providing our customers with the quality, reliability, and confidence they need to bring these products to market.”

Expanding Capacity to Meet Market Demand

The contract development and manufacturing market for liquid, suspension, semi-solid, and suppository drugs is projected to see significant growth over the next decade, with North American manufacturers playing a key role.¹ The U.S. and Canada suppositories market is projected to reach $1.3 billion by 2035, reflecting increasing acceptance of this dosage form.²

LGM Pharma’s investment will strengthen both infrastructure and quality systems at the Rosenberg facility, enhancing its ability to manufacture prescription drug products, including topical and suppository products, while maintaining the highest regulatory and quality standards.

Hamilton Lenox, Chief Commercial Officer of LGM Pharma, added, “We currently manufacture prescription products at our oral solid dose facility in Irvine, California. The Rosenberg expansion will elevate this site to the same high standards, allowing us to support customers developing liquid, suspension, semi-solid, and suppository prescription drug products with the same level of expertise and quality assurance from a U.S.-based manufacturing site.”

Strengthening U.S. Pharmaceutical Manufacturing

As supply chain disruptions, tariffs, and global uncertainties continue to impact pharmaceutical manufacturing, LGM Pharma’s investment provides a dependable domestic solution. The expansion also includes track and trace serialization capabilities at the Rosenberg facility, aligning with regulatory requirements to enhance product traceability and ensure compliance.

Companies developing 505(b)(2), NDA, ANDA, branded or generic prescription drug products are encouraged to explore LGM Pharma’s expanded manufacturing capabilities by visiting LGMPharma.com or meeting with company executives at DCAT Week (March 17-20, 2025) in New York City.